NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $1.62 0.00 (0.00%) Closing price 09/28/2026 04:00 PM EasternExtended Trading$1.65 +0.03 (+1.85%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Karyopharm Therapeutics Stock (NASDAQ:KPTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KPTI alerts:Sign Up Key Stats Today's Range$1.54▼$1.6650-Day Range$1.54▼$7.8652-Week Range$1.24▼$10.99Volume326,527 shsAverage Volume1.40 million shsMarket Capitalization$36.74 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on nuclear transport, particularly the role of exportin 1 (XPO1) in regulating the movement of proteins and RNA between a cell’s nucleus and cytoplasm. Karyopharm’s primary product is selinexor, an oral selective inhibitor of XPO1. In the United States, selinexor is marketed as XPOVIO for certain patients with multiple myeloma and diffuse large B-cell lymphoma, in combination with specified therapies or under defined treatment circumstances. The company continues to study selinexor in additional hematologic malignancies and solid tumors, as well as in combination with other cancer treatments. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built its business around its proprietary Selective Inhibitor of Nuclear Export platform. The company serves patients primarily through its commercial operations in the United States and through international partnerships and licensing arrangements. Outside the United States, selinexor is marketed in certain territories under the name NEXPOVIO by Menarini Group companies.AI Generated. May Contain Errors. Read More Karyopharm Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreKPTI MarketRank™: Karyopharm Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 254th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKaryopharm Therapeutics has a consensus price target of $11.50, representing about 609.9% upside from its current price of $1.62.Amount of Analyst CoverageKaryopharm Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($4.70) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted35.27% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 5.01.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 19.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.36 News SentimentKaryopharm Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Karyopharm Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows4 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38.00 in company stock.Percentage Held by Insiders1.68% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPTI Stock News HeadlinesFinancial Comparison: Milestone Pharmaceuticals (NASDAQ:MIST) vs. Karyopharm Therapeutics (NASDAQ:KPTI)September 27 at 2:15 AM | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) versus vTv Therapeutics (NASDAQ:VTVT) Critical SurveySeptember 25, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 29 at 1:00 AM | Altimetry (Ad)BioAge Labs (NASDAQ:BIOA) and Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head ReviewSeptember 21, 2026 | americanbankingnews.comKaryopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial UpdatesSeptember 4, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)September 3, 2026 | theglobeandmail.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | prnewswire.comKaryopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisAugust 31, 2026 | finanznachrichten.deSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $7.36 on January 1st, 2026. Since then, KPTI stock has decreased by 78.0% and is now trading at $1.62. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Thursday, August, 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by $0.95. The company earned $33.43 million during the quarter, compared to analyst estimates of $32.19 million. Read the conference call transcript. When did Karyopharm Therapeutics' stock split? Karyopharm Therapeutics shares reverse split on the morning of Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Karyopharm Therapeutics IPO? Karyopharm Therapeutics (KPTI) raised $102 million in an initial public offering on Wednesday, November 6th 2013. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS). Company Calendar Last Earnings8/13/2026Today9/29/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KPTI's financial health is in the Red zone, according to TradeSmith. KPTI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPTI CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees228Year Founded2008Price Target and Rating Average Price Target for Karyopharm Therapeutics$11.50 High Price Target$28.00 Low Price Target$3.00 Potential Upside/Downside+609.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($13.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.04 million Net Margins-153.28% Pretax Margin-153.30% Return on EquityN/A Return on Assets-145.18% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.76 Sales & Book Value Annual Sales$146.07 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value($16.00) per share Price / Book-0.10Miscellaneous Outstanding Shares22,680,000Free Float22,300,000Market Cap$36.74 million OptionableOptionable Beta0.95 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:KPTI) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts